ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.

"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

According to the latest study from BCC Research, the demand for RNA Sequencing: Technologies and Global Markets is expected to grow from $4.3 billion in 2024 to $10.3 billion by the end of 2029, at a ...

By deducing the possible ancient forms of a bacterial enzyme, OIST scientists have resurrected one of its ancestral versions, ...

Adding to the ever-growing list of newly discovered bacterial immune systems, we have characterized the mechanisms of an ...

Computational biologists from the National University of Singapore (NUS) have uncovered how RNA splicing—a crucial process ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

4′-Fluorouridine works against RNA-dependent RNA polymerase, an enzyme that helps viruses assemble RNA. The compound has a ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

Researchers investigate the influence of Mettl1 on energy metabolism and the maturation of heart cells after birth.

Researchers have developed TRISCO, a cutting-edge microscopy method that enables 3D RNA analysis in whole, intact mouse ...